drugset / Trial / NCT02344472
Detect V / CHEVENDO (Chemo vs. Endo)
Phase 3
Unknown
271 enrolled
University of Ulm
Celgene Corporation · collabEisai Inc. · collabNovartis Pharmaceuticals · collabRoche Pharma AG · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
Timeline
- Start
- 2015-09
- Primary completion
- 2025-01-31
- Completion
- 2025-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Eribulin | Small molecule | — | — |
| Subject | Exemestane | Small molecule | — | — |
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | Goserelin | Other / unclassified | — | — |
| Subject | Letrozole | Other / unclassified | — | — |
| Subject | Leuprolide | Other / unclassified | — | — |
| Subject | Nab-paclitaxel | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Ribociclib | Small molecule | — | — |
| Subject | Vinorelbine | Small molecule | — | — |
| Background | Pertuzumab | Monoclonal antibody | — | — |
| Background | Trastuzumab | Monoclonal antibody | — | — |